Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

By M. Baccarani, G. Saglio, J. Goldman, Andreas Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger and 9 more. Blood, 2006

1,349 citations recorded by the source corpus.

Subfields: Genetics, Hematology

View Paper: https://www.semanticscholar.org/paper/c7bc3eebe26fb470c296a8bc8d9a840b6158eea1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Zhesheng Chen
2. C. Ashby
3. J. Cortes
4. Andreas Hochhaus
5. H. Kantarjian
6. M. Baccarani
7. Brian J. Druker

In Hematology

1. J. Cortes
2. C. Ashby
3. Zhesheng Chen
4. Brian J. Druker
5. J. Apperley
6. Andreas Hochhaus
7. J. Goldman
8. H. Kantarjian

Citations in the corpus

• European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. (2013, methodology): “The definitions of chronic phase (CP), accelerated phase (AP), and blastic phase (BP) (Table 1) were unchanged from prior published versions.(4,5) For treatment-naı̈ve CP patients, 3 risk scores were analyzed (Table 2): Sokal, Euro, and EUTOS.”
• Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. (2009, methodology): “The prognostic value of the loss of MMolR is controversial, but all reports agree that an increase in transcript levels warrants closer monitoring.(5,39,117-124) The detection of a kinase domain mutation that employs conventional sequencing methods has a prognostic relevance, depending on the sensit”
• BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. (2010, background): “[19] Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al.”
• European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia (2020, background): “Currently, diagnosis rests on the percentage of blasts (20% or 30%) in blood or marrow [6, 94].”
• Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplant Recipients: A Global Perspective (2009, background): “However, because allogeneic HCT is associated with significant morbidity and mortality because of regimen-related toxicity (RRT) [18], infection [19], and graft versus host disease (GVHD) [20], a recommendation regarding transplantation for the individual patient requires careful risk assessment tha”
• Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial (2016, methodology): “Treatment failure was defined as no hematologic response at 3 months, no complete hematologic response or no cytogenetic response at 6 months, no partial cytogenetic response at 12 months, no CCyR at 18 months, or progression at any time.(20) Protocoldefined disease progression, on the basis of guid”